Product Dossier
LACOVIM
Product Dossier for LACOVIM (lacosamide, Pharmacor). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Pharmacor
- Active ingredient: lacosamide
- Therapeutic area: Neurology
- Related brand: VIMCOSA
- Related brand: VIMPAT
- Related brand: LACOSAM
- Same area: GILENYA
- Same area: RIVOTRIL
What it is
LACOVIM is lacosamide, available as film-coated tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg.
Approved indications —
Monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. — Add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. — Add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.
Dosing overview
LACOVIM film-coated tablets may be taken with or without food. The film-coated tablets must not be divided. Conversion to or from oral and IV administration can be done directly without titration, with the total daily dose and twice daily administration maintained. If LACOVIM has to be discontinued, it is recommended this be done gradually, for example by tapering the daily dose by 200 mg per week.
Regulatory history
LACOVIM lacosamide tablets across all strengths (50 mg, 100 mg, 150 mg and 200 mg) were first listed on the ARTG on 8 February 2022.